FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

More News

As genome sequences get cheaper, is more always better?

The time and cost of whole genome sequencing is tumbling, with Illumina and Life Technologies both announcing the launch of equipment making sequences possible in less than a day for under $1,000. What's not to like? As with everything in life, there are two sides to the story. From the biomarker research perspective, cutting the cost of sequencing is an exciting prospect—more sequences available to researchers from more individuals, or even series of sequences from the same individual through health, disease and then treatment and recovery or relapse, provide more data for comparison. The bottleneck will be processing the quantities of new data. Read more

Also Noted

> Courtagen Life Sciences acquires Medicinal Genomics, the company that sequenced the genome of the cannabis plant. Press release

> There are limited approaches for treatment for bile duct cancer, but reports from Massachusetts General Hospital Cancer Center of a new biomarker could mean the potential for a new approach to treatment. Press release

> A new antibody-based immunoassay could be useful for detecting pancreatic cancer, but has only been tested in a small group of patients so far. Article

> The U.K.-based charity Big C is funding prostate cancer biomarker research at Norwich Research Park. Article

Read more >>